— Know what they know.
Not Investment Advice

SER AMEX

Serina Therapeutics, Inc.
1W: -6.2% 1M: -25.2% 3M: +0.5% YTD: -5.8% 1Y: -62.7% 3Y: -92.4% 5Y: -94.3%
$1.96
+0.01 (+0.51%)
 
Weekly Expected Move ±11.0%
$2 $2 $2 $2 $2
AMEX · Healthcare · Biotechnology · Tech Score Strong Sell · Power 28 · $29.4M mcap · 2M float · 4.15% daily turnover · Short 39% of daily vol

Balance Sheet Trends

Total Assets
$7M +3.4% ▲
5Y CAGR: +12.1%
Total Liabilities
$7M +12.4% ▲
5Y CAGR: -5.6%
Shareholders Equity
-$37K -105.8% ▼
Cash & Investments
$3M -16.8% ▼
5Y CAGR: +42.1%
Total Debt
$196K -26.9% ▼
5Y CAGR: -50.0%
Net Debt
-$3M +16.0% ▲

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2021FY2022FY2023FY2024FY2025
— Assets —
Cash$584K$645K$8M$4M$3M
Short-Term Investments$0$0$0$0$0
Cash & ST Investments$584K$645K$8M$4M$3M
Net Receivables$25K$4K$0$0$0
Inventory$0$0$0$0$0
Other Current Assets$2M$2M$0$77K$3M
Total Current Assets$2M$2M$8M$6M$6M
Property, Plant & Equip.$0$0$1M$1M$842K
Goodwill & Intangibles$0$738K$0$0$0
Long-Term Investments$50K$50K$0$0$0
Other Non-Current Assets$870K$0$0$0$29K
Total Non-Current Assets$920K$788K$1M$1M$871K
Total Assets$3M$3M$9M$7M$7M
— Liabilities —
Accounts Payable$193K$568K$580K$744K$2M
Short-Term Debt$7M$8M$0$0$0
Deferred Revenue$0$0$0$0$0
Other Current Liabilities$2M$2M$250K$1M$2M
Total Current Liabilities$9M$10M$1M$2M$4M
Long-Term Debt$6M$10M$3M$0$196K
Other Non-Current Liab.$0$0$36M$4M$3M
Total Non-Current Liabilities$6M$10M$40M$4M$3M
Total Liabilities$15M$21M$41M$6M$7M
— Equity —
Common Stock$4K$4K$0$1K$1K
Retained Earnings-$106M-$116M-$33M-$44M-$64M
Accumulated OCI$0$0$0$0-$14K
Total Stockholders Equity-$12M-$17M-$32M$641K-$37K
Total Liabilities & Equity$3M$3M$9M$7M$7M
— Key Metrics —
Total Debt$13M$18M$3M$268K$196K
Net Debt$13M$17M-$4M-$3M-$3M
Total Investments$50K$50K$0$0$0

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms